213Bi-cDTPA-9.2.27

213Bi-cDTPA-9.2.27 is a targeted alpha therapy (TAT) radiopharmaceutical designed for the treatment of metastatic melanoma. It is an alpha-immunoconjugate (AIC) consisting of the alpha-emitting radionuclide bismuth-213 (213Bi) linked to the murine monoclonal antibody 9.2.27 via the chelator cyclic diethylenetriaminepentaacetic acid anhydride (cDTPA). The antibody 9.2.27 specifically targets the high molecular weight melanoma-associated antigen (HMW-MAA), also known as chondroitin sulfate proteoglycan 4 (CSPG4), which is highly expressed on the surface of melanoma cells. Upon binding to the target cells, the bismuth-213 emits high-linear energy transfer (LET) alpha particles that cause lethal double-strand DNA breaks within a short range (50-100 µm), effectively killing the tumor cells while sparing distant healthy tissue. Clinical development has included Phase 1 trials evaluating both intralesional and systemic administration in patients with stage IV melanoma and in-transit metastases.

Other names

Bismuth-213-cDTPA-9.2.27Bismuth213-cDTPA-9.2.27Bismuth 213-cDTPA-9.2.27213Bi-labeled 9.2.27alpha-immunoconjugate 9.2.27alpha-immunoconjugate9.2.27alpha-immunoconjugate-9.2.27